Insulet Corp. (PODD) News
Filter PODD News Items
PODD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PODD News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PODD News From Around the Web
Below are the latest news stories about INSULET CORP that investors may wish to consider to help them evaluate PODD as an investment opportunity.
Insulet Omnipod 5 insulin system available in five more European countriesMore on Insulet |
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025ACTON, Mass., January 10, 2025--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). |
Are You a Growth Investor? This 1 Stock Could Be the Perfect PickWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
Insulin Device Maker Has Analysts Turning BullishInsulet stock is near a buy point after gapping up on earnings. The company increased its full year sales guidance. |
What Does Insulet Corporation's (NASDAQ:PODD) Share Price Indicate?Insulet Corporation ( NASDAQ:PODD ) saw a double-digit share price rise of over 10% in the past couple of months on the... |
GEHC vs. PODD: Which Stock Is the Better Value Option?GEHC vs. PODD: Which Stock Is the Better Value Option? |
Insulet price target raised to $300 from $270 at BTIGBTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology names. BTIG is increasing its estimates for U.S. Omnipod sales in the second half of FY25 to reflect the anticipated tailwind of accelerated adoption that it sees happening as Insulet expands its marketing into the T2D – type 2 diabetes – patient population, the analyst tells investors in a research |
Heavy Interest in Insulet’s Insulin Delivery DeviceSales are surging for Insulet Corporation (PODD). |
Insulet Corporation (NASDAQ:PODD) Delivered A Better ROE Than Its IndustryOne of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
Why Insulet (PODD) is a Top Momentum Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |